Becton Dickinson and Co (BDX) : Amg National Trust Bank reduced its stake in Becton Dickinson and Co by 21.26% during the most recent quarter end. The investment management company now holds a total of 9,528 shares of Becton Dickinson and Co which is valued at $1,674,832 after selling 2,573 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.Becton Dickinson and Co makes up approximately 0.15% of Amg National Trust Bank’s portfolio.
Other Hedge Funds, Including , Tortoise Investment Management reduced its stake in BDX by selling 193 shares or 32.99% in the most recent quarter. The Hedge Fund company now holds 392 shares of BDX which is valued at $68,906. Becton Dickinson and Co makes up approx 0.02% of Tortoise Investment Management’s portfolio.Daiwa Securities Group reduced its stake in BDX by selling 15,788 shares or 19.83% in the most recent quarter. The Hedge Fund company now holds 63,842 shares of BDX which is valued at $11,142,344. Becton Dickinson and Co makes up approx 0.07% of Daiwa Securities Group’s portfolio.Pioneer Trust Bank N Aor reduced its stake in BDX by selling 70 shares or 3.96% in the most recent quarter. The Hedge Fund company now holds 1,697 shares of BDX which is valued at $295,957. Becton Dickinson and Co makes up approx 0.17% of Pioneer Trust Bank N Aor’s portfolio. Mai Capital Management added BDX to its portfolio by purchasing 1,269 company shares during the most recent quarter which is valued at $221,314. Becton Dickinson and Co makes up approx 0.02% of Mai Capital Management’s portfolio.Cardinal Capital Management reduced its stake in BDX by selling 3,563 shares or 4.58% in the most recent quarter. The Hedge Fund company now holds 74,237 shares of BDX which is valued at $13,038,987. Becton Dickinson and Co makes up approx 1.43% of Cardinal Capital Management’s portfolio.
Becton Dickinson and Co closed down -0.21 points or -0.12% at $173.52 with 7,51,750 shares getting traded on Monday. Post opening the session at $173.73, the shares hit an intraday low of $172.76 and an intraday high of $173.85 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.